The section of the website you selected contains information intended for US health care professionals only. Please certify that you are a US Health Care Professional by clicking the appropiate link below or close out of this window to return to the home page.

The following webpage and information therein is intended for viewing by investment audiences only. By clicking "Yes" below, you agree to be bound by the following conditions:

The following information has been prepared by ThromboGenics NV (the "Company") and is being supplied solely to investment audiences "as is" for informational purposes only. The following information may not be further distributed or passed on to any other person or published or reproduced, in whole or in part, by any medium or in any form for any purpose. All numerical data contained in the following information has been derived from ThromboGenics’ consolidated financial statements.

No representation or warranty, expressed or implied, is or will be made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the following information or opinions contained therein. The following information may be subject to updating, completion, revision, verification, and amendment, and such information may change materially. The Company is under no obligation to update or keep current the following information and any opinions expressed within are subject to change without notice. None of the Company or any of its affiliates, its advisors, or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of the following information or its contents or otherwise arising in connection with such information.

The following information does not constitute investment advice, and shall not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

ThromboGenics Business Update – Q3 2017

€53.7 million cash received from Alcon/Novartis in conjunction with regaining the non-US rights to JETREA

Company’s end Q3 2017 cash position €113.4 million

Novartis to invest €10 million in ThromboGenics’ share capital

Highlights

In September, ThromboGenics announced that it regained the non-US rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that ThromboGenics is a better fit for building a smaller but sustainable long-term business with this unique drug for the treatment of vitreomacular adhesion/ vitreomacular traction. ThromboGenics now owns all rights to JETREA® globally.

Following the agreement with Alcon/Novartis, ThromboGenics has €113.4 million in cash, which will be used to progress its pipeline of novel disease modifying medicines for the treatment of diabetic eye disease

ThromboGenics is making good progress with its late-stage preclinical pipeline:

THR-687 (integrin antagonist) is being developed to treat a broad range of patients with diabetic retinopathy, with or without DME. THR-687 is expected to enter the clinic in H1 2018

THR-149 (selective plasma kallikrein inhibitor) is being developed to treat edema associated with diabetic retinopathy (DME). THR-149 is also expected to enter the clinic in H1 2018

In August 2017, Oncurious announced an agreement with VIB for expansion of its pipeline through the acquisition of 5 unique next generation immuno-oncology (IO) assets for the treatment of a broad spectrum of cancers

Cash and investmentswere €113.4 millionas of the end of September 2017, compared with €65.1million at the end of June 2017

Leuven, Belgium – 20 October 2017 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today issues a business update for the three-month period ending 30 September 2017.

The current pipeline consists of products with different modes of action, and allows the Company to address the four key segments of the rapidly growing diabetic eye disease market:

Non-proliferative DR

Proliferative DR

Non-proliferative DR with DME

Proliferative DR with DME

Patrik De Haes, MD ThromboGenics CEO,said: “The €53 million cash payment that we received as part of our recent agreement with Alcon/Novartis to regain the non-US rights to JETREA® provides us with significant financial resources to pursue our goal of becoming a leader in the treatment of diabetic eye disease. These increased cash resources will allow us to deliver multiple value generating milestones from our pipeline. We are confident that the significant potential of our novel disease modifying drug candidates will continue to be demonstrated over the coming years.”